Open · 75 days left D National Institutes of Health

Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)

Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
May 07, 2026
Posted Nov 6, 2024 (471 days ago)
Closes May 7, 2026 (in 75 days)

Grant Details

Opportunity Number
PAR-25-063
CFDA / ALN
93.242
Opportunity Category
Discretionary (D)
Funding Category
Health (HL)
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)

Eligibility

State governments (00) County governments (01) City or township governments (02) Special district governments (04) Independent school districts (05) Public and State controlled institutions of higher education (06) Native American tribal governments (Federally recognized) (07) Public housing authorities / Indian housing authorities (08) Native American tribal organizations (11) Nonprofits having a 501(c)(3) status with the IRS (12) Nonprofits without 501(c)(3) status (13) Private institutions of higher education (20) For-profit organizations other than small businesses (22) Small businesses (23) Others (25)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Description

The objective of this Notice of Funding Opportunity (NOFO) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to psychiatric disorders; and 2) to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.